- |
My Account- |
United States (Change Country)CUDC-101 Chemical Structure
CUDC-101 is a potent multitargeted HDAC, EGFR and HER2 inhibitor with IC50 of 4.4, 2.4, and 15.7 nM, respectively. CUDC-101 has novel structure incorporating HDAC inhibitory functionality into the pharmacophore of the EGFR and HER2 inhibitors. In most tumor cell lines tested, CUDC-101 exhibits efficient antiproliferative activity with greater potency than vorinostat (SAHA), erlotinib, lapatinib, and combinations of vorinostat/erlotinib and vorinostat/lapatinib. In vivo, CUDC-101 promotes tumor regression or inhibition in various cancer xenograft models including nonsmall cell lung cancer (NSCLC), liver, breast, head and neck, colon, and pancreatic cancers. [1][2]
[1] J. Med. Chem. 2010;3, 2000–2009
[2] Cancer Res 2010;70:3647-3656
| Molecular Weight (WM): | 434.49 |
|---|---|
| Formula: | C24H26N4O4 |
| Solubility(R.T.:25°C): | DMSO 20mg/mL |
| Water <1mg/mL | |
| Ethanol <1mg/mL |
A collection of 715 inhibitors
A collection of 271 kinase inhibitors
A collection of 785 FDA approved drugs
A collection of 144 natural products
A collection of 84 chemotherapeutic agents
A collection of 1463 bioactive compounds
A collection of 117 tyrosine kinase inhibitors
;Dr. Zhang of Tianjin Medical University CUDC-101 purchased from Selleck
;Dr. Xiangbing Meng of University of Iowa CUDC-101 purchased from Selleck
Keywords:buy CUDC-101 | CUDC-101 supplier | purchase CUDC-101 | CUDC-101 cost | CUDC-101 manufacturer | order CUDC-101 | CUDC-101 distributor
